Clinical Data Another LAG-3 setback as Regeneron drug fails phase 3 trial PharmaphorumRegeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.OncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaphorum Regeneron’s LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studiesNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
